Last reviewed · How we verify

ACEI/ARB — Competitive Intelligence Brief

ACEI/ARB (ACEI/ARB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor / Angiotensin II receptor blocker. Area: Cardiovascular.

marketed ACE inhibitor / Angiotensin II receptor blocker ACE enzyme / Angiotensin II type 1 receptor (AT1R) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ACEI/ARB (ACEI/ARB) — Capital Institute of Pediatrics, China. ACEI/ARB drugs inhibit the renin-angiotensin-aldosterone system (RAAS) to reduce blood pressure and protect organs from hypertension-related damage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACEI/ARB TARGET ACEI/ARB Capital Institute of Pediatrics, China marketed ACE inhibitor / Angiotensin II receptor blocker ACE enzyme / Angiotensin II type 1 receptor (AT1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor / Angiotensin II receptor blocker class)

  1. Capital Institute of Pediatrics, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACEI/ARB — Competitive Intelligence Brief. https://druglandscape.com/ci/acei-arb. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: